Syndex Bio Debuts Proprietary mcPCR Technology

Syndex Bio has introduced its proprietary mcPCR (methyl-copying PCR) platform, which enables “PCR for methylation,” the high-fidelity copying of both DNA methylation and the four-base genetic code during DNA amplification.

This process overcomes a fundamental limitation of PCR, which cannot amplify DNA methylation patterns that are critical for detecting many diseases, including cancer. By enabling simpler, faster, and more sensitive analysis of methylated DNA, mcPCR can help transform clinical sample testing, especially in non-invasive and small-sample biopsies for early disease detection and recurrence monitoring.

Syndex Bio also has closed an oversubscribed $15.5 million seed financing led by ARCH Venture Partners, with participation from +ND Capital, OMX Ventures, and Meltwind. The funds will support the mcPCR platform’s expansion, development of clinical workflows and applications, and build-out of the company’s R&D footprint in Cambridge, U.K.

“Syndex Bio’s mcPCR platform makes amplifying DNA methylation possible for the first time. This powerful method will redefine the sensitivity and accuracy that is achievable in DNA methylation analysis, opening new possibilities for early detection and disease monitoring,” Syndex Bio Founder/CEO Geoff Smith said. “We’re honored to have the support of investors and advisors as we advance toward clinical translation.”

In conjunction with the financing, Gautam Kollu, former chief commercial officer at Grail, has joined the newly formed Board of Directors alongside Patrick Weiss (chairman), Smith, Sean Kendall, and Eric Moessinger.

“The mcPCR platform removes the technical barriers that have long limited epigenetics, finally allowing us to tap into the highest-value segments of the molecular diagnostics market,” Kollu stated. “This capability is essential for expanding precise clinical testing across diverse disease areas, where sensitivity has historically been the bottleneck. I look forward to helping the team bring such a high-impact platform technology to the global stage.”

“This milestone is a testament to Syndex Bio’s team and their efforts in launching this foundational technology,” said Kendall, a partner at ARCH Venture Partners. “We believe mcPCR holds the potential to elevate the accuracy and speed of cancer screening and diagnosis, and look forward to seeing the company continue to go from strength to strength.”

Syndex Bio is a U.K.-based biotechnology company advancing next‑generation molecular diagnostics.